Drug intelligence / Profile preview

PSY-02

Development stage: Unknown
Lead developer: Psy Therapeutics
Modality: Small Molecules

Overview

PSY-02 is a small molecule drug developed by Psy Therapeutics for the treatment of neurological and neuropsychiatric disorders. Its primary indications are Parkinson disease (active) and Alzheimer disease (inactive). The drug is currently in preclinical development for Parkinson disease, with previous phase 2 activity reported for Alzheimer disease. The precise mechanism of action and molecular targets have not been disclosed publicly. Psy Therapeutics focuses on innovative medicines targeting nervous system diseases, including neuropsychiatric conditions[1][3].

Beyond the preview

Go deeper on PSY-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSY-02.

Explore the full profile